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Abstract
Background: A number of patients treated conservatively for breast cancer will develop loco-regional and distant
recurrences. Our aim was to determine how their occurrence may be linked to the evolution of the disease.
Methods: We analyzed 238 women treated by conservative breast surgery and breast irradiation in a single institution.
We evaluated the prognostic factors associated with loco-regional and distant recurrences and the prognostic value of
local and regional recurrences on systemic progression.
Results: After a median follow-up of 5 year (range 1–10), 16 (6.72 %) patients in the breast conservative surgery (BCS)
groups had loco-regional recurrence. For distant recurrence, 10 (4.2 %) patients had experienced distant recurrence.
Lympho-vascular invasion (HR 2.55; 95 % CI, 076 to 8.49) and an extensive intraductal component (HR, 2.22; 95 % CI,
0.69 to 7.15) and nodal status are risk factors for loco-regional recurrence (LRR) after breast conservative therapy (BCT).
Tumor size, nodal status, high histologic grade, and breast cancer diagnosed at a young age (≤35 years) are correlated
with higher distant recurrence rates after BCT.
Conclusions: Risk factors for LRR after BCS include lympho-vascular invasion, extensive inraductal component, and
high nodal status, where as risk factors for distant recurrence include tumor size, nodal status, high histologic grade,
and breast cancer diagnosed at a young age (≤35 years).
Background
The surgical treatment of breast cancer changed sub-
stantially over the past decades. There was a shift from
the orthodox treatment applying modified radical mast-
ectomy (MRM) to breast conservative surgery (BCS)
with radiotherapy [1–4]; BCS became the standard treat-
ment for patients with early breast cancer. It provides a
better quality of life for these patients and has the same
overall survival if compared with mastectomy. However,
it is associated with a higher incidence of loco-regional
recurrence. This event may be a biomarker of disease
aggressiveness as distant spread is a frequent accompani-
ment [5–11].
In this study, we collected data on 238 women treated
by BCS and breast radiotherapy in order to identify and
assess the risk factors that might predict the occurrence
of loco-regional and distant recurrence after BCS aiming
at selecting the suitable patients with high risk of local
breast recurrence after BCS.
Methods
The data of operable patients, admitted and managed at
the Surgical Oncology unit, Alexandria Faculty of Medi-
cine, between 2005 and 2014, were retrospectively
reviewed and analyzed.
The data of 238 patients were included; the following
were recorded:
– An ethical approval statement was taken from all cases.
– Age at diagnosis: young patients are defined as
younger than 35 years.
– Tumor characteristics: size, nodal status, presence of
lympho-vascular invasion, amount of intraductal
component, tumor grade, margin status, hormone
receptor, and Her2 neu status.
– The follow-up period of the patients was registered.
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– The occurrence of loco-regional recurrence or
distant metastases during the follow-up period
was recorded and considered as an end point for
follow-up.
Local recurrence is defined as recurrence in the ori-
ginal tumor bed (for BCS) or field of mastectomy.
Regional recurrence refers to metastatic disease in
the ipsilateral axilla or supraclavicular lymph nodes
alone or in combination with the involvement of ipsi-
lateral breast.
Loco-regional recurrence-free survival of patients who
underwent BCS was estimated using the Kaplan-Meier
method and compared among different categories using
log-rank tests (univariable analysis of risk factors for
loco-regional recurrence).
Distal recurrence-free survival for both groups will be
analyzed using the same test (univariable analysis of risk
factors for distal recurrence).
Associations with local recurrence after BCS were fur-
ther evaluated using multivariable Cox proportional haz-
ards regression model and summarized with hazard
ratios 95 % confidence intervals (CIs).
Associations with distal recurrence after BCS were fur-
ther evaluated using multivariable Cox regression model.
Results
Age of 35 years or younger represented 21 (8.8 %) patients
in this study. Two hundred seventeen (91.2 %) patients
had an age >35 year. Median age was 52 years (range 24–
80) (Table 1).
Invasive ductal carcinoma represented 228 (95 %)
of all patients which was considered the commonest
histopathological type in this study. Grade II breast
cancer patients were 182 (76.5 %) patients (Table 2).
Of the included 238 patients, 146 (61.3 %) patients
presented with a clinical tumor of 2 cm or less.
One hundred twenty-one (50.8 %) patients had no
pathological LNS.
Stage I–II breast cancer patients were 191 (80.3 %)
patients. Forty-seven (19.7 %) patients were stage III
breast cancer and underwent BCS. Thirteen (27.6 %)
patients had neoadjuvant chemotherapy before surgery
(Tables 3 and 4).
Luminal A subtype represented 223 (93.7 %) of all pa-
tients. Triple negative subtype represented eight (3.3 %)
of all patients. (Tables 5 and 6).
Histopathological examination revealed that 47 (19.7 %)
patients had excess intraductal component of the tumor,
whereas 58 (24.4 %) had lympho-vascular invasion.
Adjuvant radiotherapy was given to 238 (100 %) patients.
Adjuvant chemotherapy was given to 201 (84.5 %)
patients.
Hormonal therapy was given to 215 (90.3 %) pa-
tients (Table 7).
After a median follow-up of 5 years (range 1–10 years),
16 (6.72 %) patients had loco-regional recurrence (LRR),
whereas 10 (4.2 %) patients had distant recurrence.
Using the Kaplan-Meier method to determine the loco-
Table 1 Age distribution




Mean ± SD 52.0 ± 10.8








Table 3 Tumour characteristics














Table 4 Stage and procedure performed
Stage No & % Operation
I&II 191 (43 %) BCS 191 (43 %)
III 47 (21.3 %) BCS 47 (21.3 %) (13 patients after neoadjuvant
chemotherapy)
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regional recurrence-free survival and distant recurrence-
free survival; it was found to be 92.7 and 96.4 %,
respectively.
Prognostic factors for loco-regional recurrence
Analysis by the Cox proportional hazards model (Table 8),
according to treatment actually given, demonstrated that
relative risk of LRR for patients with lympho-vascular
invasion compared with those without lympho-vascular
invasion was 2.55 after BCS. The 5-year free survival of
LRR after BCS was 89.1 % for patients with lymph-
vascular invasion and 94 % for those without lympho-
vascular invasion; (Fig. 1).
Patients with high nodal status have a 2.46 times
higher risk of developing LRR after BCS compared with
those with low nodal status.
The 5-year free survival of LRR after BCS was 75 %
for N3 patients and 95.7 % for N1 patients (Fig. 2).
The relative risk of LRR for patients with intraductal
component was 2.22 times after BCS compared with
those without intraductal component. The 5-year free
survival of LRR after BCS was 92.1 % for patients with
intraductal component and 92.8 % for patients without
intraductal component (Fig. 3).
The 5-year free survival of LRR after BCS was
94.4 % for patients who received hormonal therapy
and 81.3 % for patients who did not receive hormonal
therapy (Fig. 4).
Prognostic factors for distant recurrence
According to the results of the multivariate Cox
proportional hazards survival analysis, tumor size,
nodal status, and histologic grade were all highly
predictor factors of distant recurrence after BCS
(Table 9).
In addition, young age is an independent predictor of
distant recurrence after BCS. The 5-year free survival
of distant recurrence after BCS was 90.9 % for patient
aged 35 years and younger and 97 % for patients over
35 years (Fig. 5).
Hormonal therapy is also a protecting factor against
distant recurrence after BCS with HR = 0.17; CI 95 % =
0.033–0.91. The 5-year survival of distant recurrence
after BCS was 97.5 % for patients who received hormo-
nal therapy and 85.7 % for those who did not receive
hormonal therapy (Fig. 6).
Table 5 Hormone receptors
















Table 6 Biological subtypes
Type No %
Luminal A 223 93.7
Luminal B 4 1.7
Triple negative 8 3.3
Her2 enriched 3 1.3
Table 7 Adjuvant treatment
Adjuvant treatment Patients
Chemotherapy No: 37 (15.5 %)
Yes: 201 (84.5 %)
Radiotherapy Yes: all cases
Hormonal No: 23 (9.7 %)
Yes: 215 (90.33 %)
Table 8 Cox regression for loco-regional recurrence
Variables in the equation
Operation type B SE Sig. HR 95.0 % CI for HR
Lower Upper
BCT Age .003 .024 .901 1.003 .957 1.052
T .244 .680 .719 1.277 .337 4.839
LNs .900 .691 .193 2.461 .635 9.541
Stage −.911 .885 .303 .402 .071 2.277
Grade −1.322 .603 .028 .267 .082 .870
IDC .799 .596 .180 2.223 .691 7.151
Invasion .938 .613 .126 2.555 .768 8.497
Postop_chemo −1.137 .745 .127 .321 .074 1.382
Horm −1.858 .658 .005 .156 .043 .567
HR > 1 is considered as a risk factor
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Discussion
The surgical treatment of breast cancer has been chan-
ged during the previous decades towards a less extensive
surgery. Breast conservative surgery (BCS) is a model of
this type of surgery which in properly selected patients
provides local control of the disease. Based on the sys-
temic disease concept of cancer breast, the removal of
the primary does not obviate the risk of distant spread.
Thus, our concern in the present study was to analyze
the risk factors associated with loco-regional recurrence
after BCS as local recurrence will obviate the purpose of
breast conservation [12, 13].
The study revealed that the presence of an extensive
intraductal component (EIC), lympho-vascular invasion
and nodal status are associated with an increased risk of
LRR after BCS.
EIC is an established risk factor for LRR after breast
conservative therapy (BCT) [5, 14–16]. Invasive breast
carcinoma is accompanied by an extensive component
of DCTS in 15–30 % of patients.
DCIS grows along the ducts in the breast without in-
vasion of the underlying tissue, which results in a non-
palpable lesion difficult to remove with tumor-free mar-
gins. When EDCIs are completely removed with nega-
tive tumor margins, it loses its predicative value for LRR
[5, 14–19]. In a pooled analysis of the EORTC 10801
and the DBCG 82 TM trials, lympho-vascular invasion
causes a higher risk of LRR after BCT [20].
Fig. 1 A Kaplan-Meier plot showing LRR-free survival by lympho-
vascular invasion in BCS group
Fig. 2 A Kaplan-Meier plot showing LRR-free survival by nodal status
in BCS group
Fig. 3 A Kaplan-Meier plot showing LRR-free survival by intraductal
component in BCS group
Fig. 4 A Kaplan-Meier plot showing LRR-free survival by hormonal
therapy in BCS group
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This result is also concordant with the observations
made by Salim Alrahbi et al., Zahra MA Mohammed et
al., and Bent Ejlertsen et al. [21–23].
In agreement with others, positive nodal status is a
predictor for LRR in patients of BCT group [24]. Our
study suggests a favorable effect of postoperative
radiotherapy and adjuvant systemic treatment on LRR
and distant metastases for BCS [12, 13, 20]. Today,
the widespread use of adjuvant systemic therapy
(chemotherapy and endocrine therapy) for both node-
positive and node-negative breast cancer, coupled with
improvements in the mammographic and pathological
assessment of patients undergoing breast-conserving
surgery, has resulted in decreased incidence of local
failure [25, 26].
A study in Japan investigating the occurrence of
ipsilateral breast recurrence, after long-term follow-up
of patients with early breast cancer, after breast-
conservative surgery, found it to be significantly
associated with young age, positive surgical margin,
and omission of radiation therapy [27].
Our study reveals that tumor size, nodal status, and
high histologic grade are predictors for distant recur-
rence after BCS. Various studies have described an in-
creased rate of distant metastases among those patients
[14, 20, 28–33].
Patients 35 years of age or younger appeared to have
an increased risk of distant disease. The increased risk
was much more prominent after BCT.
The adverse effect of young age on prognosis has
been noted in several other studies and suggests that
breast cancer in younger women is biologically more
aggressive disease, possibly requiring more aggressive
initial treatment. The question arises whether LRR
might be a source of distant spread in some patients
in the youngest age group. Unfortunately, numbers in
the current study did not allow us to find the answer
to this question [17, 34, 35].
Conclusions
Risk factors for loco-regional recurrence and distant me-
tastases play an important role in the decision for the
treatment of breast cancer. This decision-making can be
optimized if patients at high risk for loco-regional recur-
rence can be identified.
 Lympho-vascular invasion, EIC, and high nodal
status are risk factors for LRR after BCT.
 Tumor size, nodal status, high histologic grade, and
breast cancer diagnosed at a young age (<35 years)
are correlated with higher distant recurrence rates
after BCT.
 Radiotherapy and hormonal therapy have a great
role in decreasing the development of recurrence
after BCS.
Table 9 Cox regression for distal recurrence
Variables in the equation
Operation type B SE Sig. HR 95.0 % CI for HR
Lower Upper
BCT Age −.014 .036 .684 .986 .919 1.057
T .897 .785 .253 2.453 .527 11.417
LNs .656 .635 .302 1.927 .555 6.692
Stage .065 .947 .945 1.067 .167 6.825
Grade .392 .744 .598 1.480 .344 6.356
IDC .132 .776 .864 1.142 .250 5.221
Invasion −1.233 .949 .194 .291 .045 1.870
Postop_XRT −.293 1.214 .809 .746 .069 8.056
Horm −1.759 .848 .038 .172 .033 .907
HR > 1 is considered as a risk factor
Fig. 5 A Kaplan-Meier plot showing distant recurrence-free survival
by age in BCS group
Fig. 6 A Kaplan-Meier plot showing distant recurrence-free survival
by hormonal therapy in BCS group
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